{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:09:17Z","timestamp":1789978157035,"version":"4.0.1"},"reference-count":30,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,10,6]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Daratumumab plus lenalidomide\/dexamethasone elicited an overall response rate of 81% (63% very good partial response or better). Adverse events were manageable and in accord with the individual toxicity profiles of daratumumab and lenalidomide\/dexamethasone.<\/jats:p>","DOI":"10.1182\/blood-2016-07-726729","type":"journal-article","created":{"date-parts":[[2016,8,17]],"date-time":"2016-08-17T02:59:34Z","timestamp":1471402774000},"page":"1821-1828","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":100,"title":["Phase 1\/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma"],"prefix":"10.1182","volume":"128","author":[{"given":"Torben","family":"Plesner","sequence":"first","affiliation":[{"name":"Vejle Hospital and University of Southern Denmark, Vejle, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik-Tobias","family":"Arkenau","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute, University College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gimsing","sequence":"additional","affiliation":[{"name":"Department of Haematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Krejcik","sequence":"additional","affiliation":[{"name":"Vejle Hospital and University of Southern Denmark, Vejle, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Lemech","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute, University College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique C.","family":"Minnema","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrik","family":"Lassen","sequence":"additional","affiliation":[{"name":"Department of Haematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Laubach","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics, Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Myeloma Unit, Division of Hematology, University of Turin, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen","family":"Lisby","sequence":"additional","affiliation":[{"name":"Genmab A\/S, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Basse","sequence":"additional","affiliation":[{"name":"Genmab A\/S, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Wang","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Raritan, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Kate","family":"Sasser","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Spring House, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Guckert","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Spring House, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"de Boer","sequence":"additional","affiliation":[{"name":"Janssen Biologics, Leiden, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nushmia Z.","family":"Khokhar","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Spring House, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Yeh","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Spring House, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela L.","family":"Clemens","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Spring House, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahamtan","family":"Ahmadi","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Spring House, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk M.","family":"Lokhorst","sequence":"additional","affiliation":[{"name":"Department of Hematology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics, Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2019111905154746600_B1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11899-013-0173-2","article-title":"Management of double-refractory multiple myeloma.","volume":"8","author":"Meadows","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"2019111905154746600_B2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1586\/17474086.2014.882764","article-title":"Current strategies for treatment of relapsed\/refractory multiple myeloma.","volume":"7","author":"Laubach","year":"2014","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"2019111905154746600_B3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple myeloma: diagnosis and treatment.","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2019111905154746600_B4","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"issue":"2","key":"2019111905154746600_B5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"key":"2019111905154746600_B6","author":"Lammerts van Bueren"},{"issue":"4","key":"2019111905154746600_B7","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1309\/74R4TB90BUWH27JX","article-title":"Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.","volume":"121","author":"Lin","year":"2004","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"2019111905154746600_B8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.leukres.2003.09.015","article-title":"Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.","volume":"28","author":"Santonocito","year":"2004","journal-title":"Leuk Res"},{"issue":"3","key":"2019111905154746600_B9","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2019111905154746600_B10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2010.030759","article-title":"Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.","volume":"96","author":"van der Veer","year":"2011","journal-title":"Haematologica"},{"key":"2019111905154746600_B11","author":"Boxhammer"},{"issue":"13","key":"2019111905154746600_B12","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma.","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"issue":"10027","key":"2019111905154746600_B13","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"2019111905154746600_B14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"issue":"s1","key":"2019111905154746600_B15","first-page":"84","article-title":"An open-label, multicenter, phase 1b study of daratumumab in combination with pomalidomide-dexamethasone and with backbone regimens in patients with multiple myeloma [abstract].","volume":"100","author":"Mateos","year":"2015","journal-title":"Haematologica"},{"key":"2019111905154746600_B16","unstructured":"US Department of Health and Human Services, National Institutes of Health, National Cancer Institute\n          Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03. http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf"},{"issue":"18","key":"2019111905154746600_B17","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111905154746600_B18","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1515\/cclm-2015-1031","article-title":"Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.","volume":"54","author":"McCudden","year":"2016","journal-title":"Clin Chem Lab Med"},{"issue":"12","key":"2019111905154746600_B19","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/leu.2015.290","article-title":"Clarification of the definition of complete response in multiple myeloma.","volume":"29","author":"Durie","year":"2015","journal-title":"Leukemia"},{"key":"2019111905154746600_B20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.4254.4254","article-title":"Understanding the dose regimen for daratumumab in patients with relapsed or refractory multiple myeloma (MM) after prior proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs): a quantitative pharmacologic perspective [abstract].","author":"Xu","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2019111905154746600_B21","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","article-title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"issue":"21","key":"2019111905154746600_B22","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111905154746600_B23","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"issue":"6 Pt 2","key":"2019111905154746600_B24","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/trf.13069","article-title":"Resolving the daratumumab interference with blood compatibility testing.","volume":"55","author":"Chapuy","year":"2015","journal-title":"Transfusion"},{"issue":"23","key":"2019111905154746600_B25","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.3571.3571","article-title":"Outcomes and management of red blood cell transfusions in mutliple myeloma patients treated with daratumumab [abstract].","volume":"126","author":"Chari","year":"2015","journal-title":"Blood"},{"key":"2019111905154746600_B26","article-title":"New mAb therapies in multiple myeloma: interference with blood transfusion compatibility testing [published online ahead of print 6 July 2016].","author":"De Vooght","journal-title":"Curr Opin Hematol"},{"issue":"6","key":"2019111905154746600_B27","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br J Haematol"},{"key":"2019111905154746600_B28","article-title":"Improved myeloma targeting by combination of the human anti-CD38 antibody daratumumab with lenalidomide and bortezomib [abstract].","author":"van der Veer","journal-title":"Blood"},{"issue":"10","key":"2019111905154746600_B29","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1038\/bcj.2011.42","article-title":"The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies.","volume":"1","author":"van der Veer","year":"2011","journal-title":"Blood Cancer J"},{"key":"2019111905154746600_B30","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma.","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/14\/1821\/1396413\/1821.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/14\/1821\/1396413\/1821.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T10:16:02Z","timestamp":1574158562000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/14\/1821\/35650\/Phase-12-study-of-daratumumab-lenalidomide-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,6]]},"references-count":30,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2016,10,6]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-07-726729","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,6]]}}}